Autopsy report · NCT02656329

International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device

“Sponsor discretion (low recruitment rate)”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 4 months before it stopped.
• 395 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

GE Healthcare

Sponsor type

Industry

Conditions

Heart Failure

Interventions

Iobenguane I -123 Injection; Implantable Cardioverter Defibrillator; Thyroid blocking; Iobenguane I -123 Injection; Implantable Cardioverter Defibrillator

Participants

395

Sites

94

Countries

Canada, Czechia, France, Germany, Hungary, Italy, Netherlands, Poland, Spain, United States

Trials that died the same way

• Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy
  “low recruitment rate” (72% match in meaning)
• Impedance Measurements in Heart Failure Patients
  “Enrollment rate too low; rate much under estimation of sponsor and investigators” (71% match in meaning)
• NHFOV Versus NCPAP to Prevent Exubation Failure
  “Poor recruitment rate” (69% match in meaning)
• Ovarian Aging in Low Grade Glioma (LGG) Treated With Temozolomide
  “Low recruitment, sponsor withdrew funding.” (69% match in meaning)
• Prospective Randomized Controlled Trial of Obstructed Defecation Surgery
  “Due to low recruitment rate” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.